002038 Beijing Sl Pharmaceutical
- 8.13
- -0.25-2.98%
Beijing Sl Pharmaceutical News
Shuanglu Pharmaceutical (002038.SZ): 2023 net profit pre-increased by 66%-100%
Gelonghui, January 26 | Shuanglu Pharmaceutical (002038.SZ) announced its 2023 annual results forecast. Net profit and profit attributable to shareholders of listed companies during the reporting period was about 39 million yuan to 47 million yuan, an increase of about 66%-100% over the same period of the previous year; net profit after deducting non-recurring profit and loss was about 20 million yuan to 250 million yuan, an increase of about 40%-75% over the same period last year; basic earnings per share were about 0.38 yuan/share - 0.46 yuan/share. During the reporting period, the company's net profit attributable to shareholders of listed companies increased significantly. The first is the company's non-recurring losses
Shuanglu Pharmaceutical (002038.SZ): Currently, sales of products such as oseltamivir, thymus pentapeptide, and interleukin-2 have increased markedly
Glonghui December 1: Some investors asked Shuanglu Pharmaceutical (002038.SZ) on the investor interactive platform, “Does the company have oseltamivir and azithromycin-related products?” The company replied that at present, sales of the company's products such as oseltamivir, thymus pentapeptide, and interleukin-2 have increased markedly.
Shuanglu Pharmaceutical (002038.SZ): Gicabine is still in phase III clinical research
Glonghui December 1: Some investors asked Shuanglu Pharmaceutical (002038.SZ) on the investor interactive platform, “Please tell me about the development progress of your gigacabine and febusil in China?” The company replied that gigabine is still in phase III clinical research, febusta has been conditionally listed in the US, and that the domestic listing application is under normal review.
Shuanglu Pharmaceutical (002038.SZ): Nippon Pharmaceutical has now completed phase III follow-up of all test subjects, and is expected to submit registration applications next year
Glonghui December 1: Some investors asked Shuanglu Pharmaceutical (002038.SZ) on the investor interactive platform, “Is the company's GLP-1 formulation expected to be registered this year?” The company replied that the Japanese drug has now completed phase III clinical trials and is in the clinical data collation stage. Currently, it has completed follow-up of all phase III subjects, and it is expected that registration applications will be submitted next year.
Shuanglu Pharmaceutical (002038.SZ): The company has no Smegalotide R&D
Gelonghui November 20 | Shuanglu Pharmaceutical (002038.SZ) said on the investor interactive platform that the company has not developed simeglutide, but the company's GLP-1 long-acting drug, duracylotide, has now completed phase III clinical enrollment and is expected to complete clinical research in the first half of next year; the GLP-1 preparation, liraglutide, is in the clinical data compilation stage. It is expected that all phase III participants will be followed up. It is expected that registration applications will be submitted next year.
Shuanglu Pharmaceutical (002038.SZ): No separate weight loss clinical studies were conducted in the GLP-1 clinical trials
On November 20, Gelonghui, on the investor interactive platform, some investors asked Shuanglu Pharmaceutical (002038.SZ), “Has the GLP-1 project currently being developed approved for obesity and overweight indications? “Don't answer by using methods such as GLP1 for lowering sugar and weight loss, etc.” The company replied that in the clinical trials of the company's GLP-1 projects, no separate weight loss clinical studies were conducted, but weight changes were observed as secondary efficacy indicators, and no marketing application has been submitted so far.
Shuanglu Pharmaceutical (002038.SZ): Long-acting libiotic has been marketed for sale, and Dapagliflozin has not yet been produced or marketed
Glonghui November 20: Some investors asked Shuanglu Pharmaceutical (002038.SZ) on the investor interactive platform, “When will your long-term whitening and Dagliflogenin plans start selling?” The company replied that the company's long-term libiotic is already on the market, and Daglizine has not yet been produced or marketed.
Shuanglu Pharmaceutical (002038.SZ): Three products plan to win the bid for centralized national drug procurement
Shuanglu Pharmaceutical (002038.SZ) issued an announcement. The company participated in the joint procurement office on November 6, 2023...
[BT Financial Report Instantaneous Analysis] Shuanglu Pharmaceutical's 2023 Quarterly Report: The balance ratio has declined, net profit has increased significantly, and net cash flow has decreased
This financial report was announced on 2023-10-25 18:30:26 Shuanglu Pharmaceutical (stock code: 002038) is a pharmaceutical biotechnology enterprise focusing on the research, development, production and operation of genetic engineering and related drugs. The company's main business covers the fields of oncology, cardiovascular and cerebrovascular, endocrine, liver disease, nephropathy, and anti-infection and trauma repair. It has multiple production bases, covering various product categories such as tablets, hard capsules, granules, injections, freeze-dried powder injections, biochemical APIs, therapeutic biological products, psychotropic drugs, etc. In terms of assets and liabilities, Shuanglu Pharmaceutical in the third quarter of 2023
Shuanglu Pharmaceutical (002038.SZ) released results for the first three quarters, with net profit of 318 million yuan, an increase of 33.46%
Shuanglu Pharmaceutical (002038.SZ) released its report for the third quarter of 2023, and achieved operating income of 7.7 in the first three quarters...
Shuanglu Pharmaceutical (002038.SZ): Obtaining a Clinical Trial Approval Notice for MBT-1608, a Class 1 New Drug
Gelonghui, October 19丨Shuanglu Pharmaceutical (002038.SZ) announced that the company recently received the “Drug Clinical Trial Approval Notice” for MBT-1608 tablets issued by the State Drug Administration (Notice No.: 2023LP02077). MBT-1608 is an anti-hepatitis C drug developed by Beijing Shuanglu Pharmaceutical Co., Ltd. in collaboration with Beijing Meibeta Pharmaceutical Research Co., Ltd. It has obtained Chinese patents (CN104151360B), Europe (UK, France, Germany, Netherlands EP2998307B), and Australia (2014268040)
Shuanglu Pharmaceutical (002038.SZ): Diapin, a patented variety developed jointly with the University of Michigan in the US, is currently in the preclinical stage
According to the Zhitong Financial App, Shuanglu Pharmaceutical (002038.SZ) announced that the company's stock's closing price deviation for three consecutive trading days on October 12, 2023, October 13, 2023, and October 16, 2023 was over 20%. According to the relevant regulations of the Shenzhen Stock Exchange, this is an abnormal fluctuation in stock trading. The company said that the company's ongoing research project, GLP-1 receptor agonist (Japanese formulation), has now completed follow-up with all participants in phase III and is currently in the clinical data compilation stage. Preliminary results show that the curative effects of the company's developed products and the original drug Novartis are basic
Shuanglu Pharmaceutical (002038.SZ): Currently, the company has not invested in the pharmaceutical business sector
Glonghui September 15 丨 Some investors asked Shuanglu Pharmaceutical (002038.SZ) on the investor interactive platform, “Is your company's recent sales goal to enter the pharmaceutical business chain or the healthcare system?” The company replied that the company's business has always focused on pharmaceutical R&D, production and sales. The company invested in Xinmileage Health Industry Co., Ltd. through the Jiaxing Yihe Fund to invest in the medical industry, but this does not indicate that the company has changed its main business. Currently, the company has not invested in the pharmaceutical business sector. There are no major investment plans in these two areas in the future.
Shuanglu Pharmaceutical (002038.SZ): Liraglutide is in the third phase of data collation
Glonghui September 15 丨 Some investors asked Shuanglu Pharmaceutical (002038.SZ) on the investor interactive platform, “When will your company mass-produce liraglutide?” The company replied that liraglutide is in the third phase of data consolidation.
Shuanglu Pharmaceutical (002038.SZ): The technical review of long-term biotin has been completed, and the document preparation review and approval is in progress
Glonghui September 15 丨 Some investors asked Shuanglu Pharmaceutical (002038.SZ) on the investor interactive platform, “Is the listing review of Long-Term Lixiangsu normal up to now (2023-9-12)? Are you currently awaiting CDE approval or is the CDE awaiting your submission of information?” The company replied that the company's long-term technology review has been completed and that the document preparation review and approval is being carried out.
Shuanglu Pharmaceutical (002038.SZ): The GLP-1 preparation is currently in the phase III clinical data summary and collation stage, and the weekly preparation is already in phase III clinical trials
Gelonghui September 15 丨 Some investors asked Shuanglu Pharmaceutical (002038.SZ) on the investor interactive platform, “How is your company's diet medicine progressing?” The company replied that the company's GLP-1 preparation is currently in the phase III clinical data summary and collation stage, and the weekly preparation is already in phase III clinical trials.
Shuanglu Pharmaceutical (002038.SZ): Net profit increased 91.84% in the first half of the year to 317 million yuan
Gelonghui, August 24 丨 Shuanglu Pharmaceutical (002038.SZ) announced its 2023 semi-annual report. Operating income for the reporting period was 584 million yuan, up 5.29% year on year; net profit attributable to shareholders of listed companies was 317 million yuan, up 91.84% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 194 million yuan, up 37.28% year on year; basic earnings per share were 0.31 yuan.
Shuanglu Pharmaceutical (002038.SZ): While continuing to increase product promotion efforts, Shuanglu Pharmaceutical (002038.SZ) will seek inclusion in the medical insurance catalogue at the right time
GLONGHUI August 4 | Some investors asked Shuanglu Pharmaceutical (002038.SZ), “Is it possible for complex coenzymes to be covered by health insurance in the future? Is the company making efforts in this regard?” Shuanglu Pharmaceutical replied that complex coenzymes had not been covered by national health insurance before; they had only been included in provincial health insurance in more than 20 provinces and cities. This variety is highly safe and has accurate curative effects. While the company continues to increase the promotion of the product, it will also seek inclusion in the medical insurance catalogue at the right time.
Shuanglu Pharmaceutical (002038.SZ): The company's Shijingshan plant, Changping plant, Daxing plant, and Haidian headquarters have not been affected by the torrential rain
GLONGHUI, August 4: An investor asked Shuanglu Pharmaceutical (002038.SZ), “Has the recent torrential rain had an adverse effect on the company? There are rumors that the company's warehouse base has been flooded. Are there any similar conditions? Can you tell me about it?” Shuanglu Pharmaceutical replied that the areas affected by the torrential rain in Beijing were mainly in the suburbs of Mentougou, Fangshan, etc. The company's Shijingshan factory area, Changping factory area, Daxing factory area, and Haidian headquarters have not been affected by the torrential rain so far.
Shuanglu Pharmaceutical (002038.SZ): Daglizin is currently not online
GLONGHUY August 4: Some investors asked Shuanglu Pharmaceutical (002038.SZ), “It's been 4 months since Daglizin tablets were approved in March. Why haven't they been online yet?” Shuanglu Pharmaceutical replied that daglizine is currently not online. If there is any latest news, the company will communicate in due course.
Analysis
Price Target
No Data
